|
Kuznetsova M.V., Tarasov A.V., Vinuesa D.I., Sambrano V.S., Davtyan K.V., Drapkina O.M.
Atrial fibrillation in patients with left ventricular hypertrophy: which tactics is optimal for rhythm control strategy?
|
№9 / 2022
|
|
Kokorin V.A., Boeva O.I.
Prevention of stroke and systemic embolism in patients with atrial fibrillation: focus on apixaban
|
№9 / 2022
|
|
Doshchitsin V.L., Syrov A.V.
Propafenone and sotalol use in the treatment of atrial fibrillation
|
№8 / 2022
|
|
Ruyatkina L.A., Ruyatkin D.S.
Hyperthyroidism and atrial fibrillation: a tangle of interdisciplinary problems associated with COVID-19 pandemic
|
№8 / 2022
|
|
Tarzimanova A.I.
Obesity and atrial fibrillation: mechanisms of occurence and current treatment guidelines
|
№7 / 2022
|
|
Tarzimanova A.I.
The significance of non-alcoholic fatty liver disease in atrial fibrillation development: view of cardiologist
|
№5 / 2022
|
|
Alieva A.M., Reznik E.V., Teplova N.V., Totolyan G.G., Gasanova E.T., Kalova M.R., Sabanchieva E.E., Nikitin I.G.
JDP2 – a new promising biological marker in cardiovascular pathology
|
№5 / 2022
|
|
Mikhaylenko E.V., Abdullaev Sh.P., Sychev D.A., Tchubarev V.N., Skripka A.I.
Pharmacoeconomic evaluation of genotype-guided dabigatran etexilate dosing in patients with atrial fibrillation and chronic kidney disease
|
№4 (приложение) / 2022
|
|
Nikulina S.Yu., Shishkova K.Yu., Chernova A.A., Schulman V.A.
Predicting the development of atrial fibrillation using multiple logistic regression
|
№9 / 2021
|
|
Roytberg G.E., Slastnikova I.D., Sharkhun O.O.
Management of elderly patients with nonvalvular atrial fibrillation: focus on «fragile» patients
|
№5 / 2021
|
|
Poteshkina N.G., Krylova N.S., Mikheeva L.V., Khadzegova A.B.
Anticoagulant therapy in case of atrial fibrillation for patients with chronic kidney disease
|
№3 / 2020
|
|
Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A., Rayimzhanov Z.R., Redjapova N.A., Yusupov F.A.
Braking progression of nephro- and cerebrovascular complications during atrial fibrillation: opportunities of rivaroxaban
|
№1 / 2020
|
Русский
